Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Cancer
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Pregnancy
Interventions: influenza virus vaccination; Biological
Lead sponsor: Lisa Christian; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 287 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Respiratory Tract Infections
Interventions: Respiratory pathogen panel PCR test, COVID-19 antibody test; Diagnostic Test
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
Interventions: Rosuvastatin (crestor), Placebo; Drug
Lead sponsor: Gordon Bernard; Other
Eligibility: 13 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 21
States / cities: Little Rock, Alaska • Phoenix, Arizona • Stanford, California + 17 more

Conditions: Influenza
Interventions: Influenza virus vaccine (Fluviral), Influenza virus vaccine (Fluzone); Biological
Lead sponsor: ID Biomedical Corporation, Quebec; Industry
Eligibility: 50 Years and older
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 10
States / cities: Pembroke Pines, Florida • Atlanta, Georgia • Chicago, Illinois + 7 more

Conditions: Healthy Volunteers, Influenza
Interventions: Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, without adjuvant; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Tempe, Arizona • Rolling Hills Estates, California • San Diego, California + 12 more

Conditions: Influenza
Interventions: A/Vietnam/1203/04, A/Indonesia/05/05; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Decatur, Georgia • Rochester, Minnesota • St Louis, Missouri + 1 more

Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo; Drug · Biological · Other
Lead sponsor: Donald T. Weed, MD, FACS; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative, Fluzone High-Dose, vaccine, 2016-2017 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Bardstown, Kentucky • Metairie, Louisiana

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VN, IN, dk/BANG, gf/WA, bhg/QL, AS03 adjuvant, MF59 adjuvant; Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more

Conditions: H7N9 Influenza
Interventions: H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant, H7N9c high dose without adjuvant; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Decatur, Georgia • Iowa City, Iowa • Cincinnati, Ohio + 1 more

Conditions: Influenza
Interventions: DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra); Drug
Lead sponsor: Ansun Biopharma, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 42
States / cities: Carmichael, California • Chula Vista, California • La Mesa, California + 39 more

Conditions: Influenza, Human
Interventions: Seasonal LAIV, Placebo, Wild-type A/California/2009-like Influenza Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza, Virus Diseases
Interventions: H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Interventions: Fluzone Trivalent; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: COVID-19 Respiratory Infection, Influenza A, Influenza Type B, RSV Infection
Interventions: Labcorp COVID-19+Flu+RSV Test Home Collection Kit; Device
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 2 Years to 89 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Influenza, Infections, Pneumococcal
Interventions: Arm 1: E-portal message with IVR call, Arm 2: E-portal message with no IVR call, Arm 3: No e-portal message with IVR call, Arm 5: IVR call; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo, Oseltamivir; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: VAX128, Placebo; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Influenza
Interventions: Flublok® Quadrivalent Influenza Virus Vaccine, Fluarix Quadrivalent® Influenza Virus Vaccine; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Auburn, Maine

Conditions: Influenza Immunization
Interventions: Pandemic flu H5 mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more

Conditions: Influenza, COVID-19, Vaccination Willingness
Interventions: Survey; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Influenza
Interventions: VAX161 [STF2.HA5 H5N1]; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Search by objective public record fields.

Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells

Immune Responses to the Flu Shot During Pregnancy

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

STIP: Statin Trial for Influenza Patients

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

H5N1 Priming and Boosting Strategies

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

H7N9 Mix and Match With MF59 in Healthy Adults

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

Flu COVID Vaccine Views

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years